TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06472258
Drug: IV Quinine Hydrochloride
Normalized name: quinine hydrochloride
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Quinine hydrochloride in accordance to weight with loading dose 20mg salt/kg in 10% dextrose infusion followed by 10mg salt/kg infusion 8 hourly for 2 days and for 12 hourly onwards for a maximum of 7 days.
Study: NCT06181396
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Native oxytocin analog
Study: NCT05646303
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin and psychotherapy
Study: NCT06338553
Drug: Semaglutide (Rybelsus®)
Normalized name: semaglutide Oral Tablet [Rybelsus]
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 7 mg single dose of Rybelsus® by mouth once before one of the post-TZIELD® MMTTs
Study: NCT05275777
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered as an intravenous infusion.
Study: NCT06692647
Drug: Diltiazem
Normalized name: Diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration
Study: NCT06066918
Drug: Pregabalin 75mg
Normalized name: PREGABALIN 75MG CAP,UD
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 75 mg twice a day
Study: NCT04702893
Drug: Nintedanib
Normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nintedanib
Study: NCT04005209
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The experimental group will receive a ketamine intravenous infusion, initiated at 0.2 mg/kg/hr within the first 12 to 24 hours on an inpatient admission for sickle cell pain crisis, and titrated per hospital policy by the inpatient pain service.
Study: NCT05946135
Drug: Lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: taking lansoprazole + placebo for Fexuprazan Hydrochloride for 4 weeks
Study: NCT05946135
Drug: Fexuprazan Hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: taking placebo for lansoprazole + Fexuprazan Hydrochloride for 4 weeks
Study: NCT05636579
Drug: Ripasudil
Normalized name: ripasudil
DrugBank: Ripasudil (DB13165)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Daily use of Ripasudil drops
Study: NCT04510194
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin; immediate release formation; 500mg on Day 1; 500mg BID on Day 2 through Day 5; 500mg in AM and 1,000mg in PM on Day 6 through Day 14.
Study: NCT04510194
Drug: Fluvoxamine
Normalized name: Fluvoxamine
DrugBank: Fluvoxamine (DB00176)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An antidepressant, administered 50mg per day on Day 1; then 50mg twice-daily for Day 2 through Day 14
Study: NCT04510194
Drug: Ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An anti-parasitic medication administered as 390mcg/kg to 470mcg/kg per day for 3 days
Study: NCT06702618
Drug: TQB3616 capsule+Fulvestrant Injection
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TQB3616 capsule is a CDK2/4/6 inhibitor and Fulvestrant injection is an anti-estrogen medication, and its pharmacological mechanism mainly exerts its therapeutic effect by inhibiting the action of aromatase.
Study: NCT06703606
Drug: MARSTACIMAB
Normalized name: Marstacimab
DrugBank: Marstacimab (DB17725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marstacimab 150 mg administered subcutaneous (SC) once weekly (QW)
Study: NCT06703658
Drug: AZD5004(Part A)
Normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of AZD5004 oral on Day1
Study: NCT06703658
Drug: AZD5004(Part B)
Normalized name: SODIUM CHLORITE 0.0256 kg in 1 kg TOPICAL SPRAY [Chlorsan 105 Part B]
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AZD5004 will be administered as an oral tablet once daily.
Study: NCT05169307
Drug: CPX-351
Normalized name: CPX
DrugBank: DPCPX (DB12946)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a retrospective, non-interventional, observational study. No study drug will be administered in this study.
Study: NCT04175704
Drug: UB-221
Normalized name: UB-612
DrugBank: UB-612 (DB16444)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Name: UB-221 Active ingredient: Anti-IgE monoclonal antibody Dosage form: UB-221 drug product is presented as a sterile liquid for intravenous (IV) infusion. Each vial contains 75 mg/mL UB-221 in 1.12 mL of buffered solution
Study: NCT06121557
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine will be administered at 30 mg/m\^2 IV daily for three days. Fludarabine will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
Study: NCT05416697
Drug: CBD oil
Normalized name: MENTHOL, UNSPECIFIED FORM 10 g in 100 g / CAMPHOR (NATURAL) 3 g in 100 g TOPICAL CREAM [ETERNAL SPIRIT BEAUTY PAINLESS WITH CBD OIL 3000]
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subjects will receive cannabis 2.7 mg THC 2.5 mg CBD twice daily (1 droplet twice daily; 0.73 mg THC and 0.81 mg CBD/drop, 1.46 mg THC and 1.62 CBD/day) for 1 week then titrate up to 2 droplets twice daily if tolerated (2.92 mg THC and 3.24 CBD per day) and continue the treatment until the end of the study.
Study: NCT06727812
Drug: HRS-6208
Normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-6208.
Study: NCT05597436
Drug: Trehalose
Normalized name: Trehalose
DrugBank: Trehalose (DB12310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly 0.75g/kg administration
Study: NCT04775212
Drug: Desﬂurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: compare effects of inhaled anaesthetic desflurane and sevoflurane on liver functions.
Study: NCT04775212
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane
Study: NCT00210340
Drug: intrathecal rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT05952869
Drug: Enlicitide Decanoate
Normalized name: decanoic acid
DrugBank: Capric acid (DB03600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT05465733
Drug: Envafolimab;Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: single agent, 300mg Q3W IH until disease progressed,The duration of treatment with Envafolimab should not exceed 2 years.
Study: NCT05949099
Drug: Nirogacestat
Normalized name: NIROGACESTAT
DrugBank: Nirogacestat (DB12005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nirogacestat 150 mg by mouth twice-daily continuously for Cycles 1 through 3. Treatment with nirogacestat may continue via this study protocol for up to 24 months (26 cycles of treatment), unless there is progression of disease, intolerance, start of new anticancer therapy, or Subject Study Completion or Termination occurs.
Study: NCT04770610
Drug: OT-101 Ophthalmic Solution
Normalized name: OT-730
DrugBank: OT-730 (DB16112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.01%
Study: NCT04313335
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Duloxetine (up to 60 mg per day) will be given, titrated, tapered in accordance with the pain intensity during the acute herpes zoster period.
Study: NCT05342584
Drug: Venetoclax Oral Tablet
Normalized name: venetoclax Oral Tablet
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05342584
Drug: Daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05342584
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05517603
Drug: AJ201
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered orally
Study: NCT00002118
Drug: Zalcitabine
Normalized name: Zalcitabine
DrugBank: Zalcitabine (DB00943)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06050863
Drug: Chlorhexidin
Normalized name: Chlorhexidin
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: chlorhexidine is used
Study: NCT00027040
Drug: Selegiline hydrochloride
Normalized name: Selegiline Hydrochloride
DrugBank: Selegiline (DB01037)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06498739
Drug: Erector spinae plane block(15 ml bupivacaine 0.5%)
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will preoperatively receive high concentration-low volume ultrasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room (one syringe of 15 ml bupivacaine 0.5% {15 ml bupivacaine 0.5% }, for each patient).
Study: NCT06498739
Drug: Erector spinae plane block (15 ml bupivacaine 0.5% and 15ml normal saline)
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will preoperatively receive low concentration-high volume ultrasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room ) one syringe of 30ml bupivacaine 0.25% {15 ml bupivacaine 0.5% and 15ml normal saline}, for each patient.
Study: NCT05877001
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg, IV, Q3W
Study: NCT05877001
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 80 mg once daily for the first 3 weeks of each 4-week cycle
Study: NCT06512441
Drug: Vitamin B6 Tablets
Normalized name: vitamin B6 Oral Tablet
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The experimental group was given a Vitamin B6 tablet（10mg/tablet）once a day for 3weeks, besides of the standard IBD treatment.
Study: NCT03240211
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200 mg IV
Study: NCT03240211
Drug: Pralatrexate
Normalized name: Pralatrexate
DrugBank: Pralatrexate (DB06813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pralatrexate 20 or 30 mg/m2 IV push
Study: NCT03240211
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine 10 mg/m2
Study: NCT05746351
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: a group will receive epidural Bupivacaine with Dexmedetomidine in normal labor
Study: NCT05746351
Drug: Nalbuphine
Normalized name: Nalbuphine
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a group will receive epidural Bupivacaine with Nalbuphine in normal labor
Study: NCT06232473
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Please see arm description
Study: NCT05515601
Drug: Mirikizumab
Normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT06555003
Drug: Drug-Eluting Embolic Bead
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A minimum of 2 sessions of DEBIRI treatment and 2-4 cycles of systemic chemotherapy are administered (based on tumor size, bilobar or unilobar involvement of the liver, treatment response rate, treatment tolerance, occurrence of side effects, and liver function). Prior to performing DEBIRI, initial angiography is done via the femoral or axillary artery to determine the anatomy of the right and left hepatic arteries as well as the arteries supplying the tumor. Subsequently, a vial of irinotecan (100 mg) eluted with a vial of beads(hepaSphere 25mg) is injected into the blood vessels feeding the tumor. The intervention will be repeated to deliver 200 mg of irinotecan intravascularly to the liver mass. A 14-day interval between the procedures is established to minimize side effects. Targeted therapy administration for each treatment group based on oncologist's decision and will be tailored to the tumor characteristics and the patient's clinical status as explained in control arm.
Study: NCT06555003
Drug: Chemotherapy drug
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group will receive 2-4 cycles of systemic chemotherapy based on functional status of the patient, adverse event rate and treatment tolerance, tumor size and characteristics. Targeted therapy administration for each treatment group in based on oncologist's decision and will be tailored to the tumor characteristics and the patient's clinical status (e.g., administration of Pembrolizumab for patients with high rosatellite instability (MSI-H) or Bevacizumab for tumors harboring KRAS mutations). Due to the targeted nature of these therapies, they can not be administered to all participants of the trial, while It is not ethically justifiable to withhold targeted therapies from patients who are candidates for these treatments based on their tumor characteristics and deprive them of potentially life-extending options.
Study: NCT05855122
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pateients enrolled in Tocilizumab group will receive tocilizumab(8mg/kg) at day -7 before transfusion of stem cells.
Study: NCT05818124
Drug: Molnupiravir
Normalized name: Molnupiravir
DrugBank: Molnupiravir (DB15661)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Four molnupiravir 200 mg capsules (800 mg total dose) taken twice daily by mouth.
Study: NCT05818124
Drug: Placebo molnupiravir
Normalized name: Molnupiravir
DrugBank: Molnupiravir (DB15661)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Four placebo capsules matched to molnupiravir taken twice daily by mouth.
Study: NCT05818124
Drug: Placebo oseltamivir
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo capsule matched to oseltamivir taken twice daily by mouth.
Study: NCT05818124
Drug: Oseltamivir
Normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One capsule of oseltamivir 75 mg taken twice daily by mouth.
Study: NCT05911009
Drug: BC 007 or matching placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will be treated with two infusions of BC 007 or placebo two weeks apart, according to a double-blind design
Study: NCT03277170
Drug: Montelukast Oral Granules
Normalized name: montelukast Oral Granules
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast granules, 30 mg, mixed with applesauce
Study: NCT05066997
Drug: Dexamethasone ophthalmic suspension (OCS-01)
Normalized name: Dexamethasone Ophthalmic Suspension
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The interventional drug OCS-01 eye drops will be dispensed in single dose containers for each subject to have enough medication until the next visit.~Stage 1: Subjects will be dosed with eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 6 weeks (maintenance phase).~Stage 2: Subjects will be dosed with eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase).
Study: NCT05392127
Drug: Midazolam Maleate Tablets
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam Maleate Tablets single dose
Study: NCT05392127
Drug: Warfarin Sodium Tablets
Normalized name: Warfarin Sodium Tablets
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin Sodium Tablets single dose
Study: NCT05392127
Drug: Omeprazole Enteric Capsules
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole Enteric Capsules single dose
Study: NCT05392127
Drug: Vitamin K1 Tablets
Normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K1 Tablets once daily
Study: NCT05392127
Drug: Repaglinide Tablets
Normalized name: Repaglinide Tablets
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repaglinide Tablets single dose
Study: NCT05238948
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Substrate of CYP3A4
Study: NCT05238948
Drug: CKD-506
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perpetrator of CYP3A4
Study: NCT04684550
Drug: Stabilized hypochlorous acid
DrugBank: Hypochlorous acid (DB14135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of 2 puffs and gargles every 8 hours of a solution with low concentrations of S-HCLO (3-5 ppm).
Study: NCT04446793
Drug: Onvansertib
Normalized name: Onvansertib
DrugBank: Onvansertib (DB15110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/m\^2 will be administered orally on Day 1 to Day 5 of every 14 day treatment course. There will be two 14-day courses of treatment in each 28 day cycle.
Study: NCT05076851
Drug: Proxalutamide
Normalized name: Proxalutamide
DrugBank: Proxalutamide (DB16065)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proxalutamide +ADT（Androgen Deprivation Therapy） ，Route of Proxalutamide administration: tablet, dosage：300mg , dosage form oral , frequency of administration：QD
Study: NCT05699746
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 130 mg/m2 IV day 1, combined with Capecitabine, for at most 8 cycles.
Study: NCT01134692
Drug: Propranolol, Norfloxacin, VSL#3
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol: as per heart rate titration Norfloxacin: 400mg BD
Study: NCT05804305
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol is a prostaglandin E1 analogue
Study: NCT05920512
Drug: Sodium valproate extended-release tablets
Normalized name: valproate Extended Release Oral Tablet
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium valproate extended-release tablets 0.5g/day; sirolimus tablets 1mg/day and calcitriol capsules 0.25μg/day.
Study: NCT00000748
Drug: Sulfamethoxazole-Trimethoprim
Normalized name: sulfamethoxazole-trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04808154
Drug: SNP-630
Normalized name: SNP-ACTH (1-39)
DrugBank: SNP-ACTH (1-39) (DB18544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive one single dose of SNP-630 at Day 1. Blood and urine samples will be obtained to determine the PK of orally administered SNP-630.
Study: NCT05952856
Drug: Enlicitide Decanoate
Normalized name: decanoic acid
DrugBank: Capric acid (DB03600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT06357806
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg/10ml/1bottle
Study: NCT06357806
Drug: Peg-IFNα-2b
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180ug/0.5ml/1bottle
Study: NCT05218850
Drug: Butyrate
Normalized name: butyrate
DrugBank: Butyric Acid (DB03568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butyrate enemas will be administered once a day for 12 weeks
Study: NCT05279833
Drug: dronedarone
Normalized name: Dronedarone
DrugBank: Dronedarone (DB04855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form is tablet and route of administration is oral
Study: NCT05279833
Drug: sotalol
Normalized name: Sotalol
DrugBank: Sotalol (DB00489)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form is tablet and route of administration is oral
Study: NCT05404945
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 400 mg IV
Study: NCT05404945
Drug: Vinblastine
Normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinblastine 6mg/m2 IV
Study: NCT05404945
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine 375mg/m2 IV
Study: NCT05404945
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin 1.8 mg/kg IV
Study: NCT05508776
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet (may be film-coated depending on brand)~Route of administration: Orally~400 mg tablet
Study: NCT04749979
Drug: HCG ( eg. Choriomon )
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: giving HCG
Study: NCT05332067
Drug: Omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab dose for each specific participant is based on that participant's weight and total IgE level. Omalizumab is provided by the manufacturer in two strengths:~• For Injection: 75 mg/0.5 mL and 150 mg/mL solution in a single-dose prefilled syringe
Study: NCT05599126
Drug: Mianserin
Normalized name: mianserin
DrugBank: Mianserin (DB06148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were required to take mianserin regularly during the study period, with the effective dose being taken orally once a night before bedtime.
Study: NCT05599126
Drug: Lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects were required to take lorazepam regularly during the study period, with the effective dose being taken orally once a night before bedtime.